Abstract：Objective To explore the efficacy and safety of Recombinant Human Brain Natriuretic Peptide(rhBNP)titration in the treatment of refractory acute decompensated heart failure(ADHF).Methods A total of 300 patients with refractory ADHF admitted to the Ansteel Group General Hospital from June 2018 to June 2020 were selected as the research objects.They were divided into the group A(150 cases)and the group B(150 cases)according to the random odd and even number method.The group A was given rhBNP fixed dose administration scheme,and the group B was given rhBNP titration dose administration scheme.The 24 hours urine volume,systolic blood pressure(SBP),mean arterial pressure(MAP),N-terminal pro brain natriuretic peptide(NT-proBNP),aldosterone(ALD),creatinine clearance rate(CC),left ventricular ejection fraction(LVEF),pulmonary artery pressure(PAP),hospitalization time,thirty days readmission rate and adverse reactions were compared between the two groups.Results Before the treatment,there were no significant differences in 24 hours urine volume,SBP,MAP,NT-proBNP,ALD,CC,LVEF and PAP between the two groups(P>0.05).After the treatment,24 hours urine volume of the group B was higher than that of the group A,SBP,MAP,NT-proBNP,ALD,PAP values of the group B were lower than those of the group A,the differences were statistically significant(P<0.05).There were no significant differences in CC and LVEF between the two groups(P>0.05).The hospitalization time of the group B was shorter than that of the group A,thirty days readmission rate of the group B was lower than that of the group A,and the differences were statistically significant(P<0.05).There was no significant difference in total incidence of adverse reactions between the two groups(P>0.05).Conclusion Giving rhBNP titration to treat the patients with refractory ADHF,the effect of symptom relief is better,and the safety of clinical treatment is also considered.
京公网安备 11010502046607号